Sort
48,018 grants matching “immunotherapy”
Molecular Pharmacology of NKT Cell Agonists
$697,142Luc Teyton · Scripps Research Institute, The · R01 · FY2013 · AI
CAREER: Rational Design of Immune Cell-Homing Biomaterials for Immune Regulation
$696,864Hua Wang · University Of Illinois At Urbana-Champaign · · FY2022 · MPS
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$696,801Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2025 · CA
Leveraging fructose transport to create a privileged substrate to selectively fuel T cells
$696,769Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
MYCN drives a ferroptotic vulnerability in neuroblastoma
$696,725Anthony Charles Faber · Virginia Commonwealth University · R01 · FY2023 · CA
Targeting LCN2, a novel therapy for lung cancer
$696,569Thales Papagiannakopoulos · New York University School Of Medicine · R01 · FY2025 · CA
Enhancing the efficacy of immunotherapy in DLBCL using rational combination approaches
$696,529Cheryl A London · Tufts University Boston · U01 · FY2021 · CA
Therapeutic targeting MDSC-mediated immune suppression in cancer
$696,515Yulia Nefedova · Wistar Institute · R01 · FY2025 · CA
Role of the microbiota in regulating the mononuclear phagocyte system
$696,360Silvana Goldszmid · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Development of a PET Tracer Selective for Cerebral Amyloid Angiopathy
$696,340Milos D Ikonomovic · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · AG
Development of small near-infrared laser system capable of improving immune responses to vaccines (laser-based adjuvant)
$696,264David Bean · Veralase, Llc · R42 · FY2016 · AI
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies
$696,169David R Boulware · University Of Minnesota · R01 · FY2021 · AI
CATALYTIC HIV ANTIBODIES
$696,033University Of Texas Hlth Sci Ctr Houston · P01 · FY2000 · AI
A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy
$695,955Michael Karin · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2025 · CA
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer
$695,920Leopoldo Nicolas Segal · New York University School Of Medicine · R37 · FY2020 · CA
Evaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of Cancers
$695,916Robert H Blelloch · University Of California, San Francisco · R01 · FY2024 · CA
Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancer
$695,797Sanaz Memarzadeh · University Of California Los Angeles · R01 · FY2024 · CA
IMMUNOTHERAPY FOR NSCLC
$695,598Sri International · · FY2016 · Department of the Army
Home-based actigraphy to predict disability progression and enhance clinical trials in multiple sclerosis
$695,585Ellen M. Mowry · Johns Hopkins University · R01 · FY2020 · NR
Identification of genomic drivers of brain metastases in lung adenocarcinoma
$695,450Priscilla Kaliopi Brastianos · Massachusetts General Hospital · R01 · FY2022 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma
$695,450Priscilla Kaliopi Brastianos · Massachusetts General Hospital · R01 · FY2020 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma
$695,450Priscilla Kaliopi Brastianos · Massachusetts General Hospital · R01 · FY2021 · CA
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation
$695,333Katerina Abigail Politi · Yale University · R01 · FY2020 · CA
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
$695,125Antonio M Omuro · Yale University · R01 · FY2022 · CA
Investigating hypoxia as a determinant of malignant fates in pancreas cancer
$695,122Tuomas Tammela · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA